068270 - Celltrion, Inc.

Celltrion Approves A ₩100bn Buyback And Says It Will Cancel All Of It

Celltrion's board approved buying 524,384 of its own shares on the open market between September 1 and November 30, an estimated ₩100.0bn based on the ₩190,700 close the day before the resolution. That is 0.23% of the 232.6m shares outstanding and about 0.2% of a ₩43.7tn market capitalisation, but close to 10% of FY2025 net income of ₩1.03tn. The company states it plans to cancel the entire amount, which is the part worth noting, because Korean companies frequently buy without ever cancelling. It has already retired 9,598,977 shares so far in 2026, leaving 3,983,455 in treasury. The cost is not fixed: ₩100.0bn is a price-based estimate and the actual spend moves with the market. NH Investment & Securities is the executing broker, and the filing shows ₩4.46tn of headroom under the distributable-profit limit.

Fair Disclosure

Large business group status disclosure — quarterly, individual company

Company Statement on a Rumor or Media Report — “undetermined”

Material matter: Korean marketing approval sought for CTP51, a Keytruda biosimilar

Half-Year Report

Supplier Payment Terms and Dispute-Resolution Disclosure

Material matter: Korean phase 3 trial protocol amendment filed for CTP44, a Darzalex biosimilar

Material matter: US marketing approval sought for CTP55, a Cosentyx biosimilar

Preliminary Consolidated Results (Fair Disclosure)

Material matter: Korean phase 3 trial filed for CTP13 SC (Zymfentra) in rheumatoid arthritis

Material matter: US phase 3 trial filed for CTP13 SC (Zymfentra) in rheumatoid arthritis

Material matter: European phase 3 trial filed for CTP13 SC (Zymfentra), Parts 1 and 2, in rheumatoid arthritis

Material matter: European marketing approval sought for CTP55, a Cosentyx biosimilar

Material matter: European phase 3 for CTP51, a Keytruda biosimilar, halted early and withdrawn

Material matter: European phase 3 protocol amendment filed for CTP44, a Darzalex biosimilar, Parts 1 and 2

Material matter: US phase 3 trial protocol amendment filed for CTP51, a Keytruda biosimilar

Preliminary Consolidated Results (Fair Disclosure)

Treasury Share Purchase — Result Report

Material matter: Korean marketing approval sought for CTP55, a Cosentyx biosimilar

Material matter: European phase 3 Part 1 approval lapses for CTP13 SC, subcutaneous Remsima, in paediatric Crohn disease after a development strategy change

Material matter: European phase 3 Part 1 approval lapses for CTP13 SC, subcutaneous Remsima, in paediatric ulcerative colitis after a development strategy change

Corporate governance report

Large business group status disclosure — annual and Q1, individual company

Corporate governance report

Material matter: Korean marketing approval sought for CTP6 SC, a subcutaneous Herzuma formulation

Material Event — Board Approves Treasury Share Purchase

Material event report (bonus issue)

Trading plan report by an officer or major shareholder